NDA 011839 · Pfizer
Provera
Medroxyprogesterone Acetate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1959
Jun 18, 1959
Approved uses
4
Original approval plus efficacy supplements
Registered trials
183
47 Phase 3, 16 recruiting
FAERS reports
28,420
26,121 serious, 818 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia .) The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders . ) The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study reported an...
What it is approved for
From the label in effect Jun 29, 2026.
INDICATIONS AND USAGE PROVERA tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 4, 1998 Supplement 68 · Efficacy ReviewLetter
- Jul 23, 1979 Supplement 39 · Efficacy
- Jun 6, 1979 Supplement 35 · Efficacy
- Jun 18, 1959 Original approval · Type 1 - New Molecular Entity
3 products under this application
- PROVERA · MEDROXYPROGESTERONE ACETATE 5MG · TABLET, ORAL · Prescription · TE AB
- PROVERA · MEDROXYPROGESTERONE ACETATE 2.5MG · TABLET, ORAL · Prescription · TE AB
- PROVERA · MEDROXYPROGESTERONE ACETATE 10MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Medroxyprogesterone" as an intervention, any sponsor and status, largest first.
- The Evidence for Contraceptive Options and HIV Outcomes TrialPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT02550067 · 7,830 participants · Start Dec 14, 2015 · Primary completion Oct 31, 2018
Drug: DMPA; LNG and 1 more · For: HIV; Contraception
Sites: Manzini, Eswatini; Kisumu, Kenya; Brits, South Africa · 12 sites in all
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- Heart and Estrogen-Progestin Replacement Study (HERS)Pivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00319566 · 2,430 participants · Start Jul 1992
Drug: Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily · For: Coronary Heart Disease
Sites: San Francisco, California
- Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal OsteoporosisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00808132 · 1,886 participants · Start Jan 2009 · Primary completion Feb 2011
Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg; bazedoxifene 20 mg/ conjugated estrogens 0.625 mg and 3 more · For: Menopause; Osteoporosis
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 178 sites in all
- Multi-centre Clinical Trial on Hormone Replacement Treatment in ChinaPivotal-lookingStatus unknown
Peking Union Medical College HospitalAcademic, hospital or other
NCT01698164 · 1,200 participants (planned) · Start Dec 2008 · Primary completion Oct 2012
Drug: estradiol plus MPA; Ximingting Tablet and 1 more · For: Menopausal Syndrome; Cardiovascular Disease; Osteoporosis and 1 more
Sites: Beijing, China
- Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)Pivotal-lookingRecruiting
Fang WangAcademic, hospital or other
NCT07488949 · 1,000 participants (planned) · Start Apr 9, 2024 · Primary completion Dec 31, 2030
Drug: Doxycycline combined with Medroxyprogesterone; Doxycycline combined with placebo · For: Chronic Endometritis
Sites: Lanzhou, China
- Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus ErythematosusPivotal-lookingCompleted
National Center for Research Resources (NCRR)NIH
NCT00006133 · 970 participants · Start Jun 2000
Drug: estradiol; ethinyl estradiol and 2 more · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 17 sites in all
- Long-Acting Reversible ContraceptionPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT01299116 · 916 participants · Start Dec 2011 · Primary completion Jun 2016
Drug: DMPA; oral contraceptives and 3 more · For: Contraception
Sites: Chapel Hill, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- breast cancer female9,758
- breast cancer8,138
- breast cancer metastatic1,380
- meningioma854
- oestrogen receptor assay positive773
- progesterone receptor assay positive673
- pain521
- drug ineffective520
- breast cancer in situ516
- ovarian cancer499
- nausea470
- fatigue448
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,215 |
| 2005 | 2,334 |
| 2006 | 1,804 |
| 2007 | 811 |
| 2008 | 1,983 |
| 2009 | 3,953 |
| 2010 | 6,981 |
| 2011 | 1,312 |
| 2012 | 567 |
| 2013 | 249 |
| 2014 | 234 |
| 2015 | 296 |
| 2016 | 316 |
| 2017 | 264 |
| 2018 | 299 |
| 2019 | 368 |
| 2020 | 407 |
| 2021 | 320 |
| 2022 | 301 |
| 2023 | 315 |
| 2024 | 445 |
| 2025 | 883 |
| 2026 | 762 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Aug 31, 2026
PROVERA, Tablet, 10 mg (NDC 0009-0051-01). Discontinuation of the manufacture of the drug; Withdrawal from sale expected September 2026.
To Be Discontinued · updated Aug 31, 2026
PROVERA, Tablet, 2.5 mg (NDC 0009-0065-01). Discontinuation of the manufacture of the drug; Withdrawal from sale expected early October 2026.
To Be Discontinued · updated Nov 19, 2026
Provera, Tablet, 5 mg (NDC 0009-0287-01). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Provera (Medroxyprogesterone Acetate)
2024 spending
$35K
Beneficiaries
56
144 claims
Per beneficiary
$619
$3.47 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $54,369 |
| 2021 | $51,051 |
| 2022 | $43,366 |
| 2023 | $34,225 |
| 2024 | $34,680 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis.
Nabhan A, Elshafeey F, Mehrain LM, et al. · BMC Womens Health 2021 · Meta-Analysis, Systematic Review
- Genital inflammatory status and the innate immune response to contraceptive initiation.
Radzey N, Harryparsad R, Meyer B, et al. · Am J Reprod Immunol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Potential effect of immediate postpartum use of injectable contraception on lactogenesis.
Gallo MF, Schumacher FL, Lawley M, et al. · Contraception 2025 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Contraceptive efficacy and safety of DMPA-SC.
Jain J, Jakimiuk AJ, Bode FR, et al. · Contraception 2004 · Clinical Trial, Clinical Trial, Phase III
- Depot medroxyprogesterone acetate and breast cancer: a systematic review.
Zürcher A, Knabben L, von Gernler M, et al. · Arch Gynecol Obstet 2024 · Research Support, Non-U.S. Gov't, Systematic Review
- Progestagens and anti-progestagens for pain associated with endometriosis.
Brown J, Kives S, Akhtar M · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.